| Title |
Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
|
|---|---|
| Published in |
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, September 2019
|
| DOI | 10.2147/dmso.s191438 |
| Pubmed ID | |
| Authors |
Marie Bastin, Fabrizio Andreelli |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 8 | 38% |
| Spain | 3 | 14% |
| Paraguay | 1 | 5% |
| Denmark | 1 | 5% |
| United States | 1 | 5% |
| Unknown | 7 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 48% |
| Practitioners (doctors, other healthcare professionals) | 8 | 38% |
| Scientists | 2 | 10% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 13% |
| Student > Ph. D. Student | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 6 | 8% |
| Student > Master | 6 | 8% |
| Other | 11 | 14% |
| Unknown | 34 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Biochemistry, Genetics and Molecular Biology | 7 | 9% |
| Agricultural and Biological Sciences | 4 | 5% |
| Chemistry | 2 | 3% |
| Other | 6 | 8% |
| Unknown | 34 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2024.
All research outputs
#994,526
of 25,584,565 outputs
Outputs from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#55
of 1,182 outputs
Outputs of similar age
#20,786
of 350,648 outputs
Outputs of similar age from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
#6
of 43 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,182 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,648 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.